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Abstract
Background: The use of psychotropic medications and their adverse effects in frail elderly has
been debated extensively. However, recent data from European studies show that these drugs are
still frequently prescribed in nursing home residents. In Austria, prevalence data are lacking. We
aimed to determine the prevalence of psychotropic medication prescription in Austrian nursing
homes and to explore characteristics associated with their prescription.
Methods: Cross-sectional study and association analysis in forty-eight out of 50 nursing homes
with 1844 out of a total of 2005 residents in a defined urban-rural region in Austria. Prescribed
medication was retrieved from residents' charts. Psychotropic medications were coded according
to the Anatomical Therapeutic Chemical Classification 2005. Cluster-adjusted multiple logistic
regression analysis was performed to investigate institutional and residents' characteristics
associated with prescription.
Results:  Residents' mean age was 81; 73% of residents were female. Mean cluster-adjusted
prevalence of residents with at least one psychotropic medication was 74.6% (95% confidence
interval, CI, 72.0–77.2). A total of 45.9% (95% CI 42.7–49.1) had at least one prescription of an
antipsychotic medication. Two third of all antipsychotic medications were prescribed for bedtime
use only. Anxiolytics were prescribed in 22.2% (95% CI 20.0–24.5), hypnotics in 13.3% (95% CI
11.3–15.4), and antidepressants in 36.8% (95% CI 34.1–39.6) of residents. None of the institutional
characteristics and only few residents' characteristics were significantly associated with
psychotropic medication prescription. Permanent restlessness was positively associated with
psychotropic medication prescription (AOR 1.54, 95% CI 1.32–1.79) whereas cognitive impairment
was inversely associated (AOR 0.70, 95% CI 0.56–0.88).
Conclusion: Frequency of psychotropic medication prescription is high in Austrian nursing homes
compared to recent published data from other countries. Interventions should aim at reduction
and optimisation of prescriptions.
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Background
Several studies have shown high prevalences of psycho-
tropic medications in frail elderly people [1-4]. Nursing
home residents represent a frail population, requiring spe-
cial attention on adverse drug reactions due to multiple
drug use, combined with age-related pharmacokinetic
and pharmacodynamic changes [5].
Reported prevalence of psychotropic medications in nurs-
ing homes varies substantially between studies with a
range of 50% to 80% of residents with at least one psycho-
tropic medication prescription, depending on the setting,
country, and cultural background [2].
In Europe, psychotropic medications are often used to
control behavioural and psychological symptoms of
dementia (BPSD). A meta-analysis found that atypical
antipsychotics were the only psychotropic medications
that were effective in the treatment of BPSD [6]. However,
their effectiveness is restricted to aggression, agitation and
psychotic symptoms. The effects are moderate and may be
offset by severe adverse events [7,8].
Sedation, falls, extrapyramidal and anticholinergic symp-
toms are well-described adverse effects of psychotropic
medication [9,10]. Atypical and typical antipsychotics
may increase the risk of stroke and death [11-13],
although results are contradictory [12,14,15]. Benzodi-
azepines and antidepressants increase the risk of falls and
fractures [9,16,17].
Study results on determinants of psychotropic medication
prescription in nursing home residents are conflicting.
Associations between psychotropic medication prescrib-
ing and individual residents' characteristics as age, gender,
and medical conditions as well as institutional character-
istics show substantial variations throughout countries
and within the same country [2,18-21].
So far, prevalence data on psychotropic medication pre-
scription in Austrian nursing homes are lacking. Accord-
ing to a recent legal act in Austria, the so-called
"Heimaufenthaltsgesetz" [22], nursing homes are obliged
to report not only physical restraints but also chemical
restraints. Unfortunately, no national guideline defines
inappropriate prescriptions, which could act as chemical
restraint [23].
Descriptive data on routine care are a prerequisite to opti-
mise reporting of inappropriate prescription and to shape
future interventions to reduce psychotropic medication in
nursing home residents. Since many reports on adverse
effects of psychotropic medications have recently been
published, we assumed that prescription frequency would
be lower in Austria than reported in earlier prevalence
studies from other countries [2]. We aimed to determine
the prevalence of prescribed psychotropic medication and
to explore associations between psychotropic medication
prescription and institutional and residents' characteris-
tics.
We hypothesised psychotropic medication prescription to
be higher in cognitively impaired and more care-depend-
ent residents and lower in residents with dementia but
without concomitant behavioural disturbances. We also
assumed higher psychotropic prescription rates in nursing
homes with a lower resident/staff ratio.
Methods
Nursing homes and residents
We invited all 50 nursing homes providing 2005 nursing
home beds in the federal state of Vorarlberg, Austria, to
participate. Vorarlberg is an urban-rural region in the
most Western part of Austria. A total of 48 out of 50 nurs-
ing homes agreed to participate. Data collection took
place from March 2007 to September 2007. Three trained
medical doctors and one trained advanced medical stu-
dent performed data collection. The training was provided
by the principal investigator (EM). It covered a three-hour
personal instruction about psychotropic medication use
in the elderly and provision of a written instruction man-
ual on the application of the study's data collection sheets.
The study population consisted of all residents who were
present in the nursing home at the day of data collection.
All medications, which were prescribed and administered
at least once per day were retrieved from the residents'
charts by nursing staff and documented by the trained
assessors. Data on medication prescribed "as required"
were not included. Two research assistants at the Univer-
sity of Hamburg coded all medications prescribed accord-
ing to the WHO Anatomical Therapeutic Chemical
Classification (ATC 2005) [24]. Psychotropic medications
were categorised as: antipsychotics (ATC-Category N05A),
anxiolytics (N05B), hypnotics (N05C) and antidepres-
sants (N06A).
For data protection reasons, we were unable to assess res-
idents' functional status. Therefore, we chose using the
levels of long-term care need as assessed by trained physi-
cians on behalf of the Austrian Federal Act on Nursing
Care (Bundespflegegesetz, 1993) [25]. Since 2003, this
assessment has been administered to each Austrian citizen
requiring statutory offered nursing care. Level 1 is related
to a monthly amount of nursing care time of ≥ 50 to 75
hours, level 2 to ≥ 75 to 120 hours, level 3 to ≥ 120 to 160
hours, and level 4 to ≥160 to 180 hours. For and beyond
level 5 additional care is needed due to blindness or deaf-
ness, permanently required surveillance, or complete
immobility.BMC Geriatrics 2009, 9:18 http://www.biomedcentral.com/1471-2318/9/18
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Information on history of falls and fractures was retrieved
from residents' charts.
Cognitive status was determined using the Dementia
Screening Scale (DSS) [26], a validated eight-question
proxy-rating screening tool for use by nursing staff. The
items address personal, temporal, and local orientation
during the last four weeks. The optimal cut-off level indi-
cating relevant cognitive impairment has been defined as
≥ 4 points revealing a sensitivity of 89% and a specificity
of 87% for moderate to severe dementia. An advantage of
the DSS is that the number of missing cases is lower than
in the cognitive tests commonly used, e.g. Mini-Mental
State Examination or the Dementia Scale of the Brief
Assessment Schedule.
Residents' behavioural and psychological symptoms of
dementia (BPSD) were determined using an abbreviated
Cohen Mansfield Agitation Inventory [27], comprising
five items on the frequency of behavioural symptoms dur-
ing the preceding 4 weeks. Nurses who knew the residents
well were asked to rate frequency of general restlessness,
verbal agitation, handling things inappropriately, nega-
tive attitude, and aggression on a four-point Likert scale
(never, once or twice, repeatedly, permanently).
Data collection sheets and procedure have been success-
fully tested within a recently conducted study in Germany
[3]. Data entry and coding were double checked by an
independent research assistant. The ethics committee of
the federal state Vorarlberg approved the study protocol.
Statistical methods
Baseline characteristics of nursing homes and residents
were described as means ± standard deviations (SD), and
numbers and percentages. Cluster-adjustment of these
data was avoided in order to describe the raw baseline
characteristics of the study population. A cluster was
defined as a nursing home. All parameters describing psy-
chotropic medication were considered as outcomes. These
outcome variables are correlated within the clusters. Since
data were collected across a number of clusters, the fact
that each resident of a nursing home has common influ-
ences means that each individual's data must be adjusted
in order to obtain a reliable estimate of effect size and pre-
cision. Methods for cluster-adjusted estimation of preva-
lence, means and their variances are well known from
cluster-randomised trials [28,29] and are also recom-
mended for non-randomised trials [28]. Estimators
describing outcomes (e.g. prescription prevalence) were
calculated as weighted means over all clusters. Minimum
variance weights were used instead of the frequently used
cluster size weights because of their advantages in case of
unequal cluster sizes [29]. For each outcome variable the
cluster correlation was estimated by the corresponding
intracluster correlation coefficient (ICCC).
From the cluster-adjusted estimators cluster-adjusted
approximate two-sided 95% confidence intervals (CIs)
and cluster-adjusted standard deviations (SDs) were cal-
culated.
Associations of characteristics of institutions or residents
with prescription of psychotropic medication were inves-
tigated by multiple logistic regression analysis. Correla-
tion within the clusters was considered by robust variance
estimation [30,31]. Cluster-adjusted odds ratios (AORs)
were estimated in these models.
Logistic regression models were fitted separately with
regard to five different dependent variables: prescription
of any psychotropic medication and prescription of antip-
sychotic, anxiolytic, hypnotic or antidepressive medica-
tion.
The following characteristics of institutions and residents
were considered as independent variables: Age, length of
stay in the nursing home, short time nursing care, level of
long-term care need, legal guardian designated, fall during
preceding four weeks, fall during preceding 12 months,
fracture during preceding 12 months, permanent restless-
ness, permanent verbal agitation, permanently handling
things inappropriately, permanent negative attitude, per-
manent aggression, cognitive impairment, ownership of
homes, number of residents per cluster (in the study pop-
ulation), number of residents per caregiver, proportion of
trained nurses. The logistic model considering each
dependent variable was fitted in the following way: At
first, each independent variable was evaluated in a univar-
iate model. All co-variables significantly associated with
the outcome were included in a multiple model. From
this multiple model all non-significant co-variables were
deleted. The resulting multiple model was the main
model with regard to this dependent variable. Finally, to
get unified models for each of the five dependent varia-
bles, all independent variables from the five main models
were combined in the final logistic regression models,
even if the associations were not significant in each
model. Results of the final models are presented. Adjust-
ment for multiple testing was not performed, since multi-
ple hypotheses were not tested. Results are interpreted in
an explorative manner.
The level of significance was 0.05. Statistical analysis was
performed using the statistical software packages SAS 9.2
TS1M0 and STATA 10.0 (robust variance estimation in
logistic regression models).BMC Geriatrics 2009, 9:18 http://www.biomedcentral.com/1471-2318/9/18
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Results
Nursing homes and residents
A total of 1844 residents were included. Residents' mean
age was 81 years (SD 11.6, range 29–108), 73% were
female. Mean length of stay in the nursing home was 52
months (SD 67.2, range 0–571). Residents' characteristics
are displayed in Table 1.
The majority of nursing homes were owned by non-profit
organisations (85%), of these 8% were state owned, and
6% affiliated to church. Further 15% were for-profit
organisations. A small number of residents lived at a spe-
cialised dementia care unit (n = 81, 4.4%) and 53 persons
(2.9%) were admitted for intermediate care.
The mean number of residents per home was 38 (SD 21,
range 5–113). The mean number of residents per full-time
nursing staff was 2.4 (SD 0.82, range 1.53–5.50); 41%
(SD 20, range 0–100) of nursing staff were trained nurses.
Prevalence of psychotropic medication use
Mean cluster-adjusted prevalence of residents with at least
one psychotropic medication was 74.6% (95% CI 72.0–
77.2). The mean number of psychotropic medications per
resident with at least one prescription was 1.88 (95% CI
1.82–1.94).
A total of 45.9% (95% CI 42.7–49.1) had at least one pre-
scription of an antipsychotic medication. At least one typ-
ical antipsychotic medication was prescribed in 34.8%
(95% CI 31.7–37.9) of residents and an atypical antipsy-
chotic in 19.5% (95% CI 17.2–21.8). The most often pre-
scribed antipsychotic medication was prothipendyl, an
azaphenothiazin structurally related to phenothiazines. It
was prescribed in 25.9% of residents and in all but one
patient for bedtime use. Prothipendyl is an older drug not
used in most European countries due to frequent extrapy-
ramidal side effects.
Data on psychotropic medication are displayed in Table 2.
Associations of psychotropic medication with residents' 
characteristics
We could not find any statistically significant association
between psychotropic medication prescription and nurs-
ing home characteristics such as number of residents per
nursing home (univariately p = 0.406) or the proportion
of trained nurses (univariately p = 0.910). The association
between the number of residents per caregiver and psy-
chotropic medication use was borderline significant
(using three classes: baseline 1.9–2.2 residents per car-
egiver, <1.9 and >2.2): In the adjusted model including all
other covariables of the final models as described in Table
3 and Additional file 1, the AOR of "less than 1.9 residents
per caregiver" was 1.52, (95% CI 0.93–2.50, p = 0.097).
The AOR of "more than 2.2 residents per caregiver" was
1.43 (95% CI 0.99–2.06, p = 0.057).
Only few residents' characteristics were associated with
psychotropic medication prescription. Cognitive impair-
ment was inversely associated (AOR 0.70, 95% CI 0.56–
0.88). In contrast, permanent restlessness was signifi-
cantly associated with prescription of antipsychotic (AOR
1.47, 95% CI 1.33–1.64), anxiolytic (AOR 1.23, 95% CI
1.09–1.39), and hypnotic medication (AOR 1.29, 95% CI
1.11–1.49) as well as with prescription of any psycho-
tropic medication (AOR 1.54, 95% CI 1.32–1.79). Legal
guardian designated was inversely associated with antip-
sychotic medication prescription (AOR 0.66, 95% CI
0.50–0.86), as well as permanent inappropriate handling
of things with antidepressant medication prescription
(AOR 0.83, 95% CI 0.73–0.95).
Characteristics associated with psychotropic medication
prescription and the different psychotropic medications,
which turned out to be statistically significant at least
within one of the final regression models with different
outcomes, are displayed in Table 3 and Additional file 1.
Table 1: Characteristics of residents.*†
Characteristic n = 1844
Women 1340 (73)
Mean ± SD (range) age, years 81 ± 12 (29–108)
Legal guardian designated 852 (46)
Level of long-term care need
0–2 155 (8)
3–5 1031 (56)
6–7 644 (35)
Fall during preceding 12 months 711 (39)
Fracture during preceding 12 months 134 (7)
History of hip fracture 73 (4)
Agitated behaviour‡
Restlessness
once or twice 233 (13)
repeatedly/permanently 511 (28)
Verbal agitation
once or twice 171 (9)
repeatedly/permanently 399 (22)
Handling things inappropriately
once or twice 222 (12)
repeatedly/permanently 363 (20)
Negative attitude
once or twice 288 (16)
repeatedly/permanently 466 (25)
Aggression
once or twice 241 (13)
repeatedly/permanently 216 (12)
Cognitive impairment (cut-off ≥ 4) 880 (48)
Values are numbers (percentage) unless stated otherwise.
* Not cluster-adjusted.† In some items figures do not cumulate to the 
total number of residents investigated due to missing values. ‡ During 
preceding 4 weeks.BMC Geriatrics 2009, 9:18 http://www.biomedcentral.com/1471-2318/9/18
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Discussion
This large study demonstrates that almost three-fourth of
residents in nursing homes in Vorarlberg, Austria, have at
least one prescription of a psychotropic medication.
The high prevalence of psychotropic medication prescrip-
tion in our sample is comparable to results reported by
earlier studies from other countries. For Dutch and Swed-
ish nursing homes a prevalence of approximately 70% has
been reported [32,33]. Only one Finish study reported a
prevalence of 80% exceeding our finding [2]. This study
determined a 20% prevalence of typical antipsychotics
compared to almost 35% in our study. A recently pub-
lished cross-sectional study covering data from five coun-
tries found pronounced variations between countries in
prescription rates of antipsychotic medication from 11%
in Hong Kong up to 38% in Finland [34].
Our study found a proportion of 35% of residents with at
least one typical antipsychotic medication out of 46% of
Table 2: Prescribed psychotropic medication.
Residents with at least one prescription of ... n = 1375 ICCC
Any psychotropic medication 74.6 (72.0–77.2) 0.016
Antipsychotic medication 45.9 (42.7–49.1) 0.023
Conventional, low potency 31.5 (28.4–34.5) 0.025
Conventional, middle and high potency 6.4 (5.2–7.7) 0.006
Atypical 19.5 (17.2–21.8) 0.014
Anxiolytic medication 22.2 (20.0–24.5) 0.009
Benzodiazepine 21.6 (19.3–23.9) 0.011
Other 0.9 (0.4–1.3) 0.000
Hypnotic medication 13.3 (11.3–15.4) 0.017
Benzodiazepine 11.4 (9.6–13.3) 0.015
Zolpidem, Zopiclon 2.0 (1.4–2.6) 0.000
Antidepressant medication 36.8 (34.1–39.6) 0.012
Selective serotonin reuptake inhibitor 30.8 (28.2–33.5) 0.013
Tricyclic 8.2 (7.0–9.5) 0.000
Other 2.1 (1.3–2.9) 0.015
Values are cluster-adjusted percentages (95% confidence interval) and intracluster correlation coefficients (ICCC).
Table 3: Characteristics associated with psychotropic medication prescription.
Characteristics AOR (95% CI)
n = 1690*, R2 = 0.056
p-value
Age
(Years, continuous variable; AOR per 1 year increase)
0.99 (0.98–1.00) 0.025
Male
(Reference: female)
0.71 (0.54–0.93) 0.013
Level of long-term care need ≥ 4
(Reference: 0–3)
1.70 (1.28–2.26) <0.001
Legal guardian designated
(Reference: no)
1.10 (0.86–1.41) 0.452
Fall during preceding 12 months
(Reference: no)
1.66 (1.26–2.18) <0.001
Permanent restlessness
(ordinal 1–2–3–4, reference: 1 = never; AOR per 1 unit increase)
1.52 (1.30–1.76) <0.001
Permanently handling things inappropriately
(ordinal 1–2–3–4, reference: 1 = never; AOR per 1 unit increase)
0.97 (0.83–1.14) 0.728
Permanent negative attitude
(ordinal 1–2–3–4, reference: 1 = never; AOR per 1 unit increase)
1.13 (0.98–1.30) 0.100
Permanent aggression
(ordinal 1–2–3–4, reference: 1 = never; AOR per 1 unit increase)
0.87 (0.71–1.06) 0.169
Cognitive impairment (cut-off ≥ 4)
(Reference score = 3)
0.70 (0.56–0.88) 0.002
Values are cluster-adjusted odds ratios (95% confidence interval) and p-values.
R2 = Pseudo R2 by McFadden (1974).
AOR = adjusted odds ratio.
* A total of 154 residents without psychotropic medication prescription were excluded because of missing values.BMC Geriatrics 2009, 9:18 http://www.biomedcentral.com/1471-2318/9/18
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residents with any antipsychotic medication, a frequency
that has never been reported before.
The shift in the prescription practice from conventional to
atypical antipsychotics, as reported by Rapoport [35], has
obviously not yet taken place in Austria. Since bedtime
use prescription of typical antipsychotics was found to be
common and prescription of hypnotics was low, suspi-
cion can be raised upon possible inappropriate use of
antipsychotics for treatment of sleeping disorders [36].
We have confirmed the finding by Alanen et al. (2006)
that there is no significant difference in the frequency of
antipsychotic medication prescription between residents
with and without cognitive impairment [1].
In our study, antipsychotic medication prescription was
significantly associated with the presence of restlessness.
Whether these symptoms represent behavioural symp-
toms inadequately controlled by antipsychotics or
whether they are induced by antipsychotics remains
unknown. Associations should not be interpreted as cau-
sality. Nevertheless, the use of antipsychotics is not rec-
ommended for managing dementia-related wandering,
pacing or repetitive vocalisations but only for behaviour
potentially causing danger to the patient or others. In
addition, the benefit of atypical antipsychotics is likely to
be rather small despite a high risk of adverse effects [37].
Several other studies confirm the frequent prescription of
antipsychotics to control behavioural and psychological
symptoms in patients with dementia [1,38].
A publication by Hughes et al. suggests an association
between high prescription rate of antipsychotic medica-
tion and a low staff/residents ratio [39]. This finding is not
supported by our study, as we did not find an association
between prescription prevalence and nursing staff/resi-
dents ratio. A recent study from Germany reported a lower
rate of antipsychotic medication prescription despite
comparable staff/resident ratio [3]. However, external evi-
dence remains conflicting and indicates that other charac-
teristics such as treatment variations and culture of care
might be important as well [40,41].
The use of tricyclic antidepressants is not recommended
in geriatric patients [42]. We found a prescription rate of
8% compared to 30.8% for SSRIs. Comparable studies
reported significantly lower rates [3,18,43]. The inverse
association between antidepressant medication prescrip-
tion and male gender has also been reported in previous
studies [2,18,44].
Since we did not assess duration of medication prescrip-
tion, we cannot draw any conclusion about the magni-
tude of inappropriate medication according to the Beers
Criteria or other criteria.
This is the first study analysing the prevalence of psycho-
tropic medication prescription in Austrian nursing
homes. We investigated an unselected study population
consisting of 92% of all residents living in nursing homes
in the Austrian federal state of Vorarlberg. The results of
our study are likely to be transferable to other Austrian
regions since nursing home characteristics and medical
care delivered by general practitioners is comparable
throughout the country [45]. In a previous study we dem-
onstrated that the Austrian new legal act obligating nurs-
ing homes to report chemical restraints could not be
executed due to lack of reporting standards on chemical
restraints [23]. Still, this legal act could be a promising
approach achieving a reduction of psychotropic medica-
tion. Therefore, joint efforts should be undertaken in
order to develop an appropriate national reporting stand-
ard.
Our study has limitations. Data on medication prescribed
"as required" were not included since no information on
the frequency of administration was available. For data
protection reasons, we were not able to assess residents'
diagnoses. However, several studies have demonstrated
discrepancies between mental health diagnoses and the
use of psychotropic medications in nursing home resi-
dents [46,47]. Therefore, psychotropic medication use is
not expected to be associated with diagnosis of BPSD or
with major psychiatric diagnoses [1]. Also for data protec-
tion reasons, behavioural symptoms and cognitive
impairment were assessed using proxy rating instruments
rather than direct assessment. Validity of these instru-
ments might be limited.
Conclusion
This study is another piece of evidence indicating the
ongoing overuse of psychotropic medication in nursing
home residents. Our assumption that internationally
published reports on adverse effects of psychotropic med-
ication might have had an impact on prescription behav-
iour in Austrian nursing homes could not be confirmed.
There clearly is an urgent need to reduce and optimise psy-
chotropic medication prescription in Austrian nursing
homes.
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